CoChat
Sign Up
Cited by 83

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Profiling of circulating microRNAs for prostate cancer biomarker discovery

Haldrup, Christa, Kosaka, Nobuyoshi, Ochiya, Takahiro, Borre, Michael, Høyer, Soren, Orntoft, Torben F., Sorensen, Karina D.·2014·Drug Delivery and Translational Research
DOI 10.1007/s13346-013-0169-4
Open this paper in CoChat — free account

Abstract

Prostate cancer (PC) is the most frequent cancer in men in the Western world. Currently, serum prostate-specific antigen levels and digital rectal examinations are used to indicate the need for diagnostic prostate biopsy, but lack in specificity and sensitivity. Thus, many men undergo unnecessary biopsy, and better and less invasive tools for PC detection are needed. Furthermore, whereas aggressive PC should be treated immediately to prevent dissemination, indolent PC often does not progress and overtreatment should be avoided. Currently, the best predictors of aggressiveness are Gleason score and T-stage of the primary PC. Better tools to assess PC aggressiveness could aid in treatment decisions. Recently, circulating miRNAs have been suggested as potential new biomarkers for PC with diagnostic and prognostic potential. Here, to identify new serum miRNA biomarker candidates for PC, we performed genome-wide miRNA profiling of serum samples from 13 benign prostatic hyperplasia (BPH) control patients and 31 PC patients. Furthermore, we carefully reviewed the literature on circulating miRNA biomarkers for PC. Our results confirmed the de-regulation of miR-141 and miR-375, two of the most well-documented candidate miRNA markers for PC. Moreover, we identified several new potential serum miRNA markers for PC and developed three novel and highly specific (100 %) miRNA candidate marker panels able to identify 84 % of all PC patients (miR-562/miR-210/miR-501-3p/miR-375/miR-551b), 80…

Overview

Integrity signals

Registry

Crossref · 10.1007/s13346-013-0169-4

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 37

  1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81. doi: 10.1016/j.ejca.2009.12.014 . · DOI
  2. Hoogendam A, Buntinx F, de Vet HC. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Family Practice. 1999;16(6):621–6. · DOI
  3. Glaser AP, Novakovic K, Helfand BT. The impact of prostate biopsy on urinary symptoms, erectile function, and anxiety. Current Urol Reports. 2012;13(6):447–54. doi: 10.1007/s11934-012-0277-6 . · DOI
  4. Wolters T, van der Kwast TH, Vissers CJ, Bangma CH, Roobol M, Schroder FH, et al. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. The Am J Surg Pathol. 2010;34(1):35–43. doi: 10.1097/PAS.0b013e3181c3ece9 . · DOI
  5. Albertsen PC. Treatment of localized prostate cancer: when is active surveillance appropriate? Nature Rev Clin Oncol. 2010;7(7):394–400. doi: 10.1038/nrclinonc.2010.63 . · DOI
  6. Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R, Kerin MJ. Systemic miRNAs as potential biomarkers for malignancy. Int J Cancer. 2012;131(10):2215–22. doi: 10.1002/ijc.27642 . · DOI
  7. Zhou L, Zhao YP, Liu WJ, Dong J, Chen WY, Zhang TP, et al. Circulating microRNAs in cancer: diagnostic and prognostic significance. Expert Rev of Anticancer Ther. 2012;12(2):283–8. doi: 10.1586/era.11.197 . · DOI
  8. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006. doi: 10.1038/cr.2008.282 . · DOI · Paper page
  9. Chen X, Liang H, Zhang J, Zen K, Zhang CY. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 2012;22(3):125–32. doi: 10.1016/j.tcb.2011.12.001 . · DOI · Paper page
  10. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009;19(2):43–51. doi: 10.1016/j.tcb.2008.11.003 . · DOI · Paper page
  11. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nature Rev Immunol. 2002;2(8):569–79. doi: 10.1038/nri855 . · DOI
  12. Simons M, Raposo G. Exosomes—vesicular carriers for intercellular communication. Current Opinion in Cell Biol. 2009;21(4):575–81. doi: 10.1016/j.ceb.2009.03.007 . · DOI
  13. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13(4):423–33. doi: 10.1038/ncb2210 . · DOI · Paper page
  14. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12):5003–8. doi: 10.1073/pnas.1019055108 . · DOI · Paper page
  15. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223–33. doi: 10.1093/nar/gkr254 . · DOI · Paper page
  16. Ma R, Jiang T, Kang X. Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res: CR. 2012;31:38. doi: 10.1186/1756-9966-31-38 . · DOI
  17. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8. doi: 10.1073/pnas.0804549105 . · DOI · Paper page
  18. Kelly BD, Miller N, Healy NA, Walsh K, Kerin MJ. A review of expression profiling of circulating microRNAs in men with prostate cancer. BJU Int. 2013;111(1):17–21. doi: 10.1111/j.1464-410X.2012.11244.x . · DOI
  19. Selth LA, Tilley WD, Butler LM. Circulating microRNAs: macro-utility as markers of prostate cancer? Endocrine-related cancer. 2012;19(4):R99–R113. doi: 10.1530/ERC-12-0010 . · DOI
  20. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64(15):5245–50. doi: 10.1158/0008-5472.CAN-04-0496 . · DOI · Paper page
  21. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22. doi: 10.1016/j.ccr.2010.05.026 . · DOI
  22. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. British J Cancer. 2012;106(4):768–74. doi: 10.1038/bjc.2011.595 . · DOI
  23. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011;128(3):608–16. doi: 10.1002/ijc.25376 . · DOI
  24. Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate. 2012. doi: 10.1002/pros.22572 . · DOI
  25. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One. 2009;4(7):e6229. doi: 10.1371/journal.pone.0006229 . · DOI
  26. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stoppler H, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011;71(2):550–60. doi: 10.1158/0008-5472.CAN-10-1229 . · DOI
  27. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2011;71(3):326–31. doi: 10.1002/pros.21246 . · DOI
  28. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol : J Int Soc for Oncodevelopmental Biol and Med. 2011;32(3):583–8. doi: 10.1007/s13277-011-0154-9 . · DOI
  29. Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, et al. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer. 2012;131(3):652–61. doi: 10.1002/ijc.26405 . · DOI
  30. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology. 2011;77(5):1265 e9-16. doi: 10.1016/j.urology.2011.01.020 . · DOI
  31. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. The oncologist. 2010;15(7):673–82. doi: 10.1634/theoncologist.2010-0103 . · DOI
  32. Zheng C, Yinghao S, Li J. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. Med Oncol. 2012;29(2):815–22. doi: 10.1007/s12032-011-9934-8 . · DOI
  33. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012;72(13):1469–77. doi: 10.1002/pros.22499 . · DOI
  34. Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012;72(13):1443–52. doi: 10.1002/pros.22495 . · DOI
  35. Jung K. A review of expression profiling of circulating microRNAs in men with prostate cancer. BJU Int. 2013;111(1):3–4. doi: 10.1111/j.1464-410X.2012.11257.x . · DOI
  36. Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. The lancet Oncol. 2012;13(11):1114–24. doi: 10.1016/S1470-2045(12)70372-8 . · DOI
  37. Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, et al. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. The lancet Oncol. 2012;13(11):1105–13. doi: 10.1016/S1470-2045(12)70263-2 . · DOI

Cited by

Sorted by citations

See all 83

Metadata

Authors
Haldrup, C., Kosaka, N., Ochiya, T., Borre, M., Høyer, S., Orntoft, T. F., & Sorensen, K. D.
Venue
Drug Delivery and Translational Research
Publisher
Springer Science and Business Media LLC
Published
2013-08-17
Volume
4
Issue
1
Pages
19-30
ISSN
  • 2190-393X
  • 2190-3948
DOI
10.1007/s13346-013-0169-4
Cited by
83
References
1
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Profiling of circulating microRNAs for prostate cancer biomarker discovery. https://app.cochat.ai/papers/10.1007/s13346-013-0169-4
The paper
Haldrup, C., Kosaka, N., Ochiya, T., Borre, M., Høyer, S., Orntoft, T. F., & Sorensen, K. D. (2014). Profiling of circulating microRNAs for prostate cancer biomarker discovery. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-013-0169-4